- Merck & Co. reports Ifinatamab Deruxtecan shows promising response rates in Phase 2 IDeate-Lung01 trial for extensive-stage small cell lung cancer..
Sat Sep 07 18:32:08 -0000 2024 UTC– Daiichi Sankyo and Merck have announced that a 12 mg/kg dose of ifinatamab deruxtecan (I-DXd) has been selected as the optimal dose for the extension part of the ongoing IDeate-Lung01 phase 2 trial.
Promising Results
This decision is based on promising interim results demonstrating encouraging objective response rates in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC). The same dose has been chosen for the recently initiated IDeate-Lung02 phase 3 study.
Daiichi Sankyo and Merck
Ifinatamab deruxtecan is a first-in-class B7-H3 directed antibody-drug conjugate (ADC), jointly developed by Daiichi Sankyo and Merck, and it aims to target the B7-H3 protein, which is present in approximately 65% of all SCLC tumors. SCLC remains a particularly aggressive form of lung cancer with a very low five-year survival rate, especially in its metastatic stage.
The interim results were presented during a press conference and will be further discussed in an oral presentation at the 2024 World Conference on Lung Cancer. The promising data reinforce the potential of ifinatamab deruxtecan as a targeted treatment option for this challenging cancer type.
It’s still better to quit smoking
The news about ifinatamab deruxtecan shows progress in developing treatments for small cell lung cancer (SCLC), which is strongly linked to smoking. While this development is encouraging for those with SCLC, it doesn’t change the overall risks that smoking poses. The best way to prevent lung cancer and other smoking-related diseases remains quitting smoking altogether.
So, while the advancements in SCLC treatment are promising, the ideal approach to health is avoiding the risk factors associated with such diseases in the first place.
Subscribe to Lisa’s Newsletter today!
Keep Up: Nobot.News Launches Breaking Newsletter
Read more Business News as it happens!
Business